The Coalition for Epidemic Preparedness Innovations (CEPI) was founded with the mission to accelerate the development of vaccines against emerging infectious diseases (EID) and enable equitable access for all during outbreaks. Less than three years after its start, CEPI’s quick response during the COVID-19 pandemic propelled the development and manufacturing of new vaccines and it was the only entity with the mandate to invest in de-risking COVID-19 vaccine research and development (R&D) with global access in mind. CEPI’s role fills some of the critical gaps that governments do not address and on March 7-8, the U.K. Government will host the CEPI replenishment at the Pandemic Preparedness Summit. The replenishment aims to raise US$3.5 billion for the delivery of CEPI’s critical 2022-2026 strategy to accelerate the development of vaccines and other health tools against epidemic and pandemic threats.
Produced by Pandemic Action Network and DSW, CEPI’s Unique Impact Opportunity: Pandemic Preparedness & Response R&D examines the characteristics and ways in which CEPI is distinctly positioned to bolster global and regional health security initiatives, especially through vaccine R&D against EIDs, to ensure the world is equipped to end the COVID crisis for everyone and is better prepared for the next pandemic.
Key messages of the brief explainer include:
- CEPI is uniquely positioned to address global pandemic threats through vaccine R&D for emerging infectious diseases.
- Because of its commitment to equitable access for the global good, particularly in low- and middle-income countries, CEPI’s work leads to increased access and distribution of much-needed vaccines to traditionally underserved populations.
- Building on its role, investments, and relationships, CEPI delivers catalytic impact globally in pandemic preparedness and response.
- CEPI fills critical gaps in the vaccine R&D ecosystem that would otherwise go unfilled.
- Emerging infectious diseases, such as COVID-19, do not recognize international borders. CEPI’s global mandate naturally complements regional and national R&D institutions that work to counter pandemic threats.
Read the full brief.
Amplify these messages using our social media toolkit.
